Iovance Biotherapeutics, Inc. (IOVA) income statement
NASDAQ · Healthcare · Biotechnology · 975 employees · CEO Frederick G. Vogt
- Price
- $8.48 -11.30%
- Market cap
- $3.84B
- Enterprise value
- $3.78B
- Last report
- Q2 '26 filed 2026-08-06
- Next report
- 2026-11-05 EPS est. -$0.08
Iovance Biotherapeutics, Inc. (IOVA) reported revenue of $99.3M for Q2 '26 (+65.7% year on year), operating income of -$51.9M (-52.3% of revenue) and net income of -$47.3M. Over the last four quarters revenue was $325M.
Income statement
| Income statement | Trend | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $469K | $482K | $715K | $31.1M | $58.6M | $73.7M | $49.3M | $60M | $67.5M | $86.8M | $71.4M | $99.3M | |
| Cost of revenue | $4.34M | $4.37M | $7.26M | $31.4M | $39.8M | $45.5M | $42.7M | $48.9M | $38.5M | $43.1M | $42.5M | $43.6M | |
| Gross profit | -$3.87M | -$3.88M | -$6.55M | -$262K | $18.7M | $28.2M | $6.61M | $11.1M | $29M | $43.7M | $28.9M | $55.7M | |
| Research & development | $87.5M | $87.5M | $79.8M | $62.1M | $68.2M | $72.2M | $76M | $77.9M | $75.2M | $71.2M | $62.5M | $58.9M | |
| Sales & marketing | $0 | $0 | $17.9M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| General & administrative | $0 | $0 | $8.26M | $0 | $39.6M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Other operating expenses | $0 | $0 | $5.27M | $5.38M | -$1K | $0 | $8.07M | $9.35M | $9.01M | $9.52M | $8.54M | $9.5M | |
| Operating expenses | $114M | $117M | $111M | $102M | $108M | $115M | $128M | $125M | $119M | $117M | $110M | $108M | |
| Operating income | -$118M | -$121M | -$118M | -$102M | -$89.1M | -$86.6M | -$121M | -$114M | -$89.8M | -$73.5M | -$81M | -$51.9M | |
| Interest income | $3.36M | $3.12M | $3.34M | $3.36M | $4.01M | $9.58M | $3.22M | $4.1M | $1.24M | $1.74M | $1.33M | $3.22M | |
| Other non-operating income (gains on investments, FX ...) | -$3.36M | -$3.12M | -$3.34M | -$3.36M | $1K | -$9.58M | $0 | $0 | $0 | $0 | $0 | $0 | |
| Total non-operating income | $3.36M | $3.12M | $3.34M | $3.36M | $4.01M | $9.58M | $3.22M | $4.1M | -$3.9M | $1.74M | $1.33M | $3.22M | |
| Income before tax | -$115M | -$118M | -$114M | -$98.6M | -$85.1M | -$77M | -$118M | -$110M | -$93.7M | -$71.7M | -$79.7M | -$48.7M | |
| Income tax | -$1.24M | -$1.76M | -$1.41M | -$1.46M | -$1.52M | $1.56M | -$1.84M | $1.99M | -$2.41M | $184K | -$665K | -$1.37M | |
| Net income | -$114M | -$116M | -$113M | -$97.1M | -$83.5M | -$78.6M | -$116M | -$112M | -$91.3M | -$71.9M | -$79M | -$47.3M | |
| EPS (basic) | -$0.46 | -$0.45 | -$0.42 | -$0.34 | -$0.28 | -$0.26 | -$0.36 | -$0.33 | -$0.25 | -$0.18 | -$0.19 | -$0.11 | |
| EPS (diluted) | -$0.46 | -$0.45 | -$0.42 | -$0.34 | -$0.28 | -$0.26 | -$0.36 | -$0.33 | -$0.25 | -$0.18 | -$0.19 | -$0.11 | |
| Shares (basic, weighted) | 246M | 256M | 266M | 285M | 303M | 305M | 323M | 335M | 364M | 407M | 419M | 450M | |
| Shares (diluted, weighted) | 246M | 256M | 266M | 285M | 303M | 305M | 323M | 335M | 364M | 407M | 419M | 450M | |
| Depreciation & amortization | $9.88M | $9.71M | $9.91M | $10.9M | $11.1M | $11.7M | $10.9M | $12.2M | $11.5M | $12.6M | $10.4M | $10.4M | |
| EBITDA | -$105M | -$108M | -$104M | -$87.7M | -$77.9M | -$65.3M | -$110M | -$102M | -$78.2M | -$60.8M | -$70.6M | -$41.5M |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.19M | $164M | $264M | |
| Cost of revenue | $978K | $952K | $956K | $8.12M | $0 | $0 | $0 | $10.8M | $124M | $173M | |
| Gross profit | -$978K | -$952K | -$956K | -$8.12M | $0 | $0 | $0 | -$9.57M | $40.1M | $90.3M | |
| Research & development | $28M | $71.6M | $99.8M | $166M | $202M | $259M | $295M | $344M | $282M | $300M | |
| General & administrative | $25.6M | $21.3M | $28.4M | $40.8M | $60.2M | $83.7M | $104M | $0 | $0 | $0 | |
| Other operating expenses | $9.5M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $35.9M | |
| Operating expenses | $53.6M | $92.9M | $128M | $207M | $262M | $343M | $399M | $451M | $435M | $489M | |
| Operating income | -$53.6M | -$92.9M | -$128M | -$207M | -$262M | -$343M | -$399M | -$461M | -$395M | -$398M | |
| Interest income | $745K | $813K | $0 | $9.32M | $2.36M | $451K | $2.99M | $13M | $20.3M | $10.3M | |
| Interest expense | $0 | $0 | $0 | $0 | $0 | $0 | $2.99M | $0 | $0 | $0 | |
| Other non-operating income (gains on investments, FX ...) | -$745K | -$813K | -$4.68M | -$9.32M | $0 | -$451K | -$5.97M | -$13M | -$20.3M | $0 | |
| Total non-operating income | $745K | $813K | $4.68M | $9.32M | $2.36M | $451K | $2.99M | $13M | $20.3M | $5.16M | |
| Income before tax | -$52.9M | -$92.1M | -$124M | -$198M | -$260M | -$342M | -$396M | -$448M | -$375M | -$393M | |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$3.48M | -$2.83M | -$2.07M | |
| Net income | -$52.9M | -$92.1M | -$124M | -$198M | -$260M | -$342M | -$396M | -$444M | -$372M | -$391M | |
| EPS (basic) | -$0.96 | -$1.41 | -$1.27 | -$1.50 | -$1.88 | -$2.23 | -$2.49 | -$1.89 | -$1.28 | -$1.09 | |
| EPS (diluted) | -$0.96 | -$1.41 | -$1.27 | -$1.50 | -$1.88 | -$2.23 | -$2.49 | -$1.89 | -$1.28 | -$1.09 | |
| Shares (basic, weighted) | 55.3M | 65.2M | 97.3M | 124M | 138M | 153M | 159M | 235M | 290M | 357M | |
| Shares (diluted, weighted) | 55.3M | 65.2M | 97.3M | 124M | 138M | 153M | 159M | 235M | 290M | 357M | |
| Depreciation & amortization | $978K | $952K | $956K | $8.12M | $1.14M | $14M | $21.1M | $33.1M | $43.6M | $47.3M | |
| EBITDA | -$51.9M | -$91.1M | -$123M | -$189M | -$261M | -$328M | -$372M | -$414M | -$331M | -$351M |
Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data as of 2026-11-02